GlassScriptPhysician profile
Mary H Strizzi
NPI 1619104841
$1,993.01
in general payments reported to CMS, 2019-2025
22 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $82.67 · 2021: $156 · 2022: $193 · 2023: $606 · 2024: $259 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $415.61 | 2019-2024 | Da Vinci Surgical System |
| Abbvie INC. | $354.72 | 2019-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $306.79 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $145.11 | 2019-2025 | Gardasil 9 |
| Coopersurgical, INC. | $119.63 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $69.57 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $62.62 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $58.59 | 2025 | Myfembree |
| Biogen, INC. | $58.00 | 2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $55.99 | 2020-2022 | |
| Myovant Sciences INC. | $52.78 | 2021-2022 | |
| Coloplast Corp | $45.00 | 2019 | |
| Hologic Sales and Service, LLC | $44.37 | 2019-2021 | |
| Evofem Biosciences, INC. | $35.78 | 2021-2022 | |
| Therapeuticsmd, INC. | $34.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $29.70 | 2019 | |
| Baxter Healthcare | $23.98 | 2023 | Tisseel |
| Aspira Women'S Health INC | $22.37 | 2023 | Ova1 |
| Daiichi Sankyo INC. | $17.50 | 2019 | |
| Astellas Pharma Global Development | $16.66 | 2025 | Veozah |
| Agile Therapeutics, INC. | $12.25 | 2022 | |
| Allergan, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Strizzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.